With Moleculin’s WP1066 oral formulation, an externally funded Phase 2 trial in combination with radiation treating GBM, a form of brain cancer, is recruiting and treating subjects at Northwestern ...

FIRST CLINICAL TRIAL OF A NEW CANCER DRUG FOR CATS. AND IT COULD HAVE APPLICATIONS FOR HUMANS. YEAH, IT’S INTERESTING. SCIENTISTS AT UC DAVIS AND UC SAN FRANCISCO HAVE TREATED CATS WITH SQUAMOUS CELL ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

Vividion Therapeutics Inc. has patented 2-azaspiro [3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of ...

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

Triple-negative breast cancer (TNBC), which accounts for up to 20% of cases of breast cancer, is one of the most aggressive and difficult to treat subtypes of the disease.